Resources

Abstracts Presented at the CRA Annual Scientific Meeting in Halifax, Nova Scotia, April 16 – 19, 2026

This section features resources the CRA feels will be of interest to members.

Participant-reported effect of an Indigenous Health continuing professional development initiative for specialists Health outcomes of Indigenous patients are impacted by culturally unsafe specialty care environments. The ‘Educating for Equity (E4E)’ program is a continuing professional development (CPD) intervention which incorporates […]

The Canadian Scleroderma Research Group teamed up with the Australian Scleroderma Interest Group to developed a new set of inclusion/exclusion criteria for stem cell transplantation that can act as guide to Canadian rheumatologists. The criteria were based on the results […]

This report will provide a brief summary of what we, at the CRA, have been up to thanks primarily to our committed members and the support of our partners and friends.

This Canadian Rheumatology Association (CRA) guideline provides contemporary recommendations for the pharmacological management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drug (DMARD) therapy. Recommendations are developed using the GRADE approach with a multidisciplinary panel composed of rheumatologists, researchers, methodologists, and […]

The management of axial spondyloarthritis (axSpA) is a complex and rapidly changing field for Canadian rheumatologists. The Spondyloarthritis Research Consortium of Canada (SPARCC) and the Canadian Rheumatology Association (CRA) last updated treatment recommendations for the management of axSpA in 2014(1,2). […]

There are currently significant discrepancies between Canadian provinces and territories in the criteria for access to advanced targeted agents for rheumatoid arthritis (RA) treatment. Such targeted agents include biologic medications as well as small molecule inhibitors. In hopes of supporting […]

The antimalarial drugs, hydroxychloroquine (HCQ) and rarely chloroquine, are essential drugs in the treatment of rheumatic diseases. HCQ is currently the only anti-malarial drug available in Canada for the treatment of rheumatic diseases...

The Canadian Rheumatology Association (CRA) strongly opposes Bill 2, recently enacted by the Government of Quebec. This legislation introduces coercive measures that undermine physicians’ rights, destabilize the health care system, and threaten the quality of care for patients living with […]

This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals […]

Abstracts Presented at the CRA Annual Scientific Meeting in Calgary, Alberta, February 26-March 1, 2025